(CNK) Cinemark Holdings - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US17243V1026
Stock: Motion Picture Exhibition, Theatre Operations, Concessions, Screen Advertising
Total Rating 28
Risk 60
Buy Signal -1.09
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.22% |
| Yield on Cost 5y | 1.69% |
| Yield CAGR 5y | % |
| Payout Consistency | 70.1% |
| Payout Ratio | 46.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 35.0% |
| Relative Tail Risk | -6.52% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.34 |
| Alpha | -21.92 |
| Character TTM | |
|---|---|
| Beta | 0.277 |
| Beta Downside | 0.342 |
| Drawdowns 3y | |
|---|---|
| Max DD | 38.38% |
| CAGR/Max DD | 0.81 |
Description: CNK Cinemark Holdings January 10, 2026
Cinemark Holdings, Inc. (NYSE:CNK) is a publicly traded motion-picture exhibitor operating a network of theatres across the United States and Latin America. Founded in 1984 and headquartered in Plano, Texas, the company generates revenue primarily from ticket sales, concessions, and advertising.
Key operating metrics include FY 2023 revenue of roughly $2.2 billion and a comparable-store (same-theatre) ticket-sales growth of 5 % year-over-year, driven by a modest rebound in discretionary consumer spending post-pandemic. The average ticket price has risen to about $12.30, reflecting both inflationary pressure and premium-format pricing (e.g., IMAX, 4DX). Core sector drivers remain the health of the U.S. economy, consumer confidence, and the competitive landscape with streaming services, while Latin American markets add geographic diversification but expose the firm to currency and political risk.
For a deeper, data-rich analysis of CNK’s valuation and risk profile, you might explore the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 154.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.66 > 1.0 |
| NWC/Revenue: -6.89% < 20% (prev -0.70%; Δ -6.19% < -1%) |
| CFO/TA 0.10 > 3% & CFO 444.7m > Net Income 154.8m |
| Net Debt (2.63b) to EBITDA (540.4m): 4.88 < 3 |
| Current Ratio: 0.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (123.8m) vs 12m ago -21.74% < -2% |
| Gross Margin: 52.32% > 18% (prev 0.42%; Δ 5190 % > 0.5%) |
| Asset Turnover: 67.30% > 50% (prev 58.24%; Δ 9.06% > 0%) |
| Interest Coverage Ratio: 2.05 > 6 (EBITDA TTM 540.4m / Interest Expense TTM 166.6m) |
Altman Z'' -0.02
| A: -0.05 (Total Current Assets 680.9m - Total Current Liabilities 898.1m) / Total Assets 4.44b |
| B: -0.02 (Retained Earnings -87.6m / Total Assets 4.44b) |
| C: 0.07 (EBIT TTM 341.4m / Avg Total Assets 4.69b) |
| D: -0.12 (Book Value of Equity -480.8m / Total Liabilities 4.04b) |
| Altman-Z'' Score: -0.02 = B |
Beneish M -3.14
| DSRI: 0.99 (Receivables 142.0m/131.2m, Revenue 3.15b/2.87b) |
| GMI: 0.81 (GM 52.32% / 42.17%) |
| AQI: 1.12 (AQ_t 0.39 / AQ_t-1 0.35) |
| SGI: 1.10 (Revenue 3.15b / 2.87b) |
| TATA: -0.07 (NI 154.8m - CFO 444.7m) / TA 4.44b) |
| Beneish M-Score: -3.14 (Cap -4..+1) = AA |
What is the price of CNK shares?
As of February 07, 2026, the stock is trading at USD 25.77 with a total of 1,580,502 shares traded.
Over the past week, the price has changed by +8.83%, over one month by +13.22%, over three months by -10.82% and over the past year by -15.78%.
Over the past week, the price has changed by +8.83%, over one month by +13.22%, over three months by -10.82% and over the past year by -15.78%.
Is CNK a buy, sell or hold?
Cinemark Holdings has received a consensus analysts rating of 3.90.
Therefore, it is recommended to buy CNK.
- StrongBuy: 3
- Buy: 4
- Hold: 2
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the CNK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 31.5 | 22% |
| Analysts Target Price | 31.5 | 22% |
| ValueRay Target Price | 27 | 4.9% |
CNK Fundamental Data Overview February 03, 2026
P/E Trailing = 21.1429
P/E Forward = 11.8765
P/S = 0.8823
P/B = 4.9091
P/EG = 1.7222
Revenue TTM = 3.15b USD
EBIT TTM = 341.4m USD
EBITDA TTM = 540.4m USD
Long Term Debt = 1.87b USD (from longTermDebt, last quarter)
Short Term Debt = 370.7m USD (from shortTermDebt, last quarter)
Debt = 3.10b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.63b USD (from netDebt column, last quarter)
Enterprise Value = 5.42b USD (2.78b + Debt 3.10b - CCE 461.3m)
Interest Coverage Ratio = 2.05 (Ebit TTM 341.4m / Interest Expense TTM 166.6m)
EV/FCF = 19.45x (Enterprise Value 5.42b / FCF TTM 278.5m)
FCF Yield = 5.14% (FCF TTM 278.5m / Enterprise Value 5.42b)
FCF Margin = 8.83% (FCF TTM 278.5m / Revenue TTM 3.15b)
Net Margin = 4.91% (Net Income TTM 154.8m / Revenue TTM 3.15b)
Gross Margin = 52.32% ((Revenue TTM 3.15b - Cost of Revenue TTM 1.50b) / Revenue TTM)
Gross Margin QoQ = 20.98% (prev 63.43%)
Tobins Q-Ratio = 1.22 (Enterprise Value 5.42b / Total Assets 4.44b)
Interest Expense / Debt = 1.21% (Interest Expense 37.5m / Debt 3.10b)
Taxrate = 21.0% (US default 21%)
NOPAT = 269.7m (EBIT 341.4m * (1 - 21.00%))
Current Ratio = 0.76 (Total Current Assets 680.9m / Total Current Liabilities 898.1m)
Debt / Equity = 8.08 (Debt 3.10b / totalStockholderEquity, last quarter 383.4m)
Debt / EBITDA = 4.88 (Net Debt 2.63b / EBITDA 540.4m)
Debt / FCF = 9.46 (Net Debt 2.63b / FCF TTM 278.5m)
Total Stockholder Equity = 579.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.30% (Net Income 154.8m / Total Assets 4.44b)
RoE = 26.70% (Net Income TTM 154.8m / Total Stockholder Equity 579.7m)
RoCE = 13.94% (EBIT 341.4m / Capital Employed (Equity 579.7m + L.T.Debt 1.87b))
RoIC = 9.88% (NOPAT 269.7m / Invested Capital 2.73b)
WACC = 3.79% (E(2.78b)/V(5.88b) * Re(6.94%) + D(3.10b)/V(5.88b) * Rd(1.21%) * (1-Tc(0.21)))
Discount Rate = 6.94% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 1.91%
[DCF Debug] Terminal Value 88.43% ; FCFF base≈258.3m ; Y1≈318.7m ; Y5≈542.7m
Fair Price DCF = 112.1 (EV 15.80b - Net Debt 2.63b = Equity 13.17b / Shares 117.5m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 51.44 | EPS CAGR: 40.94% | SUE: -1.71 | # QB: 0
Revenue Correlation: 44.13 | Revenue CAGR: 6.94% | SUE: 1.25 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.14 | Chg30d=-0.119 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=2.12 | Chg30d=+0.003 | Revisions Net=-5 | Growth EPS=+87.1% | Growth Revenue=+9.2%
P/E Forward = 11.8765
P/S = 0.8823
P/B = 4.9091
P/EG = 1.7222
Revenue TTM = 3.15b USD
EBIT TTM = 341.4m USD
EBITDA TTM = 540.4m USD
Long Term Debt = 1.87b USD (from longTermDebt, last quarter)
Short Term Debt = 370.7m USD (from shortTermDebt, last quarter)
Debt = 3.10b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.63b USD (from netDebt column, last quarter)
Enterprise Value = 5.42b USD (2.78b + Debt 3.10b - CCE 461.3m)
Interest Coverage Ratio = 2.05 (Ebit TTM 341.4m / Interest Expense TTM 166.6m)
EV/FCF = 19.45x (Enterprise Value 5.42b / FCF TTM 278.5m)
FCF Yield = 5.14% (FCF TTM 278.5m / Enterprise Value 5.42b)
FCF Margin = 8.83% (FCF TTM 278.5m / Revenue TTM 3.15b)
Net Margin = 4.91% (Net Income TTM 154.8m / Revenue TTM 3.15b)
Gross Margin = 52.32% ((Revenue TTM 3.15b - Cost of Revenue TTM 1.50b) / Revenue TTM)
Gross Margin QoQ = 20.98% (prev 63.43%)
Tobins Q-Ratio = 1.22 (Enterprise Value 5.42b / Total Assets 4.44b)
Interest Expense / Debt = 1.21% (Interest Expense 37.5m / Debt 3.10b)
Taxrate = 21.0% (US default 21%)
NOPAT = 269.7m (EBIT 341.4m * (1 - 21.00%))
Current Ratio = 0.76 (Total Current Assets 680.9m / Total Current Liabilities 898.1m)
Debt / Equity = 8.08 (Debt 3.10b / totalStockholderEquity, last quarter 383.4m)
Debt / EBITDA = 4.88 (Net Debt 2.63b / EBITDA 540.4m)
Debt / FCF = 9.46 (Net Debt 2.63b / FCF TTM 278.5m)
Total Stockholder Equity = 579.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.30% (Net Income 154.8m / Total Assets 4.44b)
RoE = 26.70% (Net Income TTM 154.8m / Total Stockholder Equity 579.7m)
RoCE = 13.94% (EBIT 341.4m / Capital Employed (Equity 579.7m + L.T.Debt 1.87b))
RoIC = 9.88% (NOPAT 269.7m / Invested Capital 2.73b)
WACC = 3.79% (E(2.78b)/V(5.88b) * Re(6.94%) + D(3.10b)/V(5.88b) * Rd(1.21%) * (1-Tc(0.21)))
Discount Rate = 6.94% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 1.91%
[DCF Debug] Terminal Value 88.43% ; FCFF base≈258.3m ; Y1≈318.7m ; Y5≈542.7m
Fair Price DCF = 112.1 (EV 15.80b - Net Debt 2.63b = Equity 13.17b / Shares 117.5m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 51.44 | EPS CAGR: 40.94% | SUE: -1.71 | # QB: 0
Revenue Correlation: 44.13 | Revenue CAGR: 6.94% | SUE: 1.25 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.14 | Chg30d=-0.119 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=2.12 | Chg30d=+0.003 | Revisions Net=-5 | Growth EPS=+87.1% | Growth Revenue=+9.2%